Antimicrobial peptide WK-13-3D protects mice from Japanese Encephalitis Virus by targeting viral envelope.

The Japanese encephalitis virus (JEV), a mosquito-borne flavivirus, poses a significant public health threat, particularly in Asia. Currently, there are no approved antiviral drugs specifically for treating JEV infection, leaving supportive care as the primary management strategy. This gap highlights an urgent need for novel therapeutic interventions. Targeting virus-host protein interactions, which are crucial for viral replication and pathogenesis, represents a promising strategy for developing new antiviral agents. The viral envelope protein, in particular, is a key player in viral entry and a prime target for inhibition.

This preclinical study investigated the antiviral efficacy of the antimicrobial peptide WK-13-3D against Japanese Encephalitis Virus (JEV) infection. Researchers utilized an in vivo mouse model of JEV infection. The core experimental design involved pre-treating JEV viral particles with WK-13-3D prior to administration to the mice. The primary endpoint was protection against mortality. The study also explored the peptide's mechanism of action, focusing on its interaction with viral particles and its effect on viral internalization, likely using in vitro assays, though specific methods like ELISA or flow cytometry were not detailed in the abstract.

Antimicrobial peptide WK-13-3D demonstrated potent antiviral activity against Japanese Encephalitis Virus (JEV). Mechanistically, the peptide inhibits JEV infection by directly binding to the viral particle. This interaction is hypothesized to involve the viral Envelope (E) protein, a critical component for viral entry. The binding of WK-13-3D to the virus effectively prevents viral internalization into host cells, thereby blocking the initial stages of infection. This in vitro mechanism translated into significant in vivo protection. > In JEV-infected mice, pre-treating the virus with WK-13-3D provided complete protection against mortality, indicating a robust therapeutic potential. This finding suggests that WK-13-3D interferes with a fundamental step of the JEV life cycle, offering a novel approach to combat this severe neurological infection.